See the Glossary for more terms.
Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.
NB: Council approval does not guarantee that a concept will become an initiative.
For the published program announcement identifying location of peer review, see the September 11, 2013, Guide announcement, Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP).
Request for Proposals
Contact: George Keane
Objective: Cure HIV infection.
Description: This initiative will provide funds and the laboratory infrastructure required to quantitate latently-infected cells in the blood of HIV-infected individuals, using the quantitative viral outgrowth assay (Q-VOA). The Q-VOA is the most accurate assay available today to measure latent virus in HIV-infected patients whose viral loads have been suppressed by antiretroviral therapy. This initiative aims to be a service resource to the HIV-eradication community by providing research laboratories with Q-VOA measurements of latent HIV.
For the published request for applications, see the July 1, 2013, Guide announcement.
Request for Applications
Contact: Alan Embry
Description: The goal of this initiative is to identify novel strategies to eliminate replication-competent HIV from infected individuals without necessitating reactivation of the latent provirus. This initiative will support research to:
Advances made in these areas will significantly accelerate the path to developing an effective strategy for curing HIV infection.
Contact: Sandra Bridges
Description: This initiative will support developing innovative approaches to improve on the current HIV treatment paradigm that requires a lifetime commitment to combination drug therapy. Approaches of interest include: cell therapies, including those based on hematopoietic stem cells; nontraditional antiviral strategies (miRNAs, siRNAs, gene-editing enzymes) and delivery of same; and novel gene therapy approaches. Programs must combine basic or preclinical research on the chosen approach and translational activities such as test-of-concept studies in animals or humans. Research in the following areas will be excluded: Zn-finger nuclease projects targeting CCR5 unless combined with another approach; gene therapies using antiviral or host targets that have already been studied; immunomodulatory strategies alone (TLR antagonists/agonists, cytokines, chemokines); and strategies that rely on frequent (e.g., daily) dosing.
For the published request for applications, see the October 24, 2013, Guide announcement.
Program Announcement Identifying Location of Peer Review
Contact: Ann Namkung Lee
Objective: To foster the highest quality AIDS research by increasing collaborations and multidisciplinary research within an institution and between institutions to enhance translation of basic research findings into concepts for HIV prevention and therapy in a synergistic and cost-effective manner.
Description: The CFAR program provides resources and core facilities to support AIDS research at institutions with a critical number of NIH-funded HIV/AIDS investigators. The initiative includes trans-NIH management of the CFAR program with FIC, NIAID, NCI, NHLBI, NICHD, NIDA, NIMH, NIA, NIGMS, NINR, NIDDK, and OAR.
All CFARs must have an administrative core that supports the management and operations of the CFAR, a developmental core, and at least one clinical and one basic core. The developmental core provides support for pilot studies to new investigators in AIDS research, evolving research opportunities, and high-risk/high-impact collaborative studies. The clinical and basic cores provide shared resources, reagents, and technology at reduced or no cost to HIV/AIDS researchers. A change in the eligibility criteria will be implemented in the next program announcement. The minimum amount of NIH AIDS research funding required to be eligible to apply for a CFAR or D-CFAR will be increased.
Contact: Dena Nannetti
Objective: To provide infrastructure to assure the quality and validity of pharmacology data generated in international and domestic laboratories participating in NIAID DAIDS-funded and collaborative clinical trials.
Description: This initiative will help assess and improve the quality of clinical pharmacology research taking place in clinical trials of interest to NIAID. It will support:
Last Updated October 24, 2013
Last Reviewed July 01, 2013